These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 38329128)

  • 1. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.
    Kim MJ; Kim S; Reinheckel T; Krainc D
    JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
    Kim MJ; Jeon S; Burbulla LF; Krainc D
    Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.
    Dobert JP; Bub S; Mächtel R; Januliene D; Steger L; Regensburger M; Wilfling S; Chen JX; Dejung M; Plötz S; Hehr U; Moeller A; Arnold P; Zunke F
    Adv Sci (Weinh); 2024 Jul; 11(25):e2401641. PubMed ID: 38666485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity.
    Kim MJ; Jeong H; Krainc D
    Hum Mol Genet; 2022 Jul; 31(14):2424-2437. PubMed ID: 35181782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of GCase Activity in Cultured Cells.
    Shojima Y; Ogata J; Tsunemi T; Imai Y; Hattori N
    Methods Mol Biol; 2021; 2322():47-52. PubMed ID: 34043191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Yang SY; Gegg M; Chau D; Schapira A
    Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
    Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
    Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocerebrosidase dysfunction in neurodegenerative disease.
    Brooker SM; Krainc D
    Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones.
    Hoshikawa T; Watanabe T; Kotake M; Tiberghien N; Woo CK; Lewis S; Briston T; Koglin M; Staddon JM; Powney B; Schapira AHV; Takle AK
    Bioorg Med Chem Lett; 2023 Feb; 81():129130. PubMed ID: 36640928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
    Yang SY; Taanman JW; Gegg M; Schapira AHV
    Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
    Menozzi E; Schapira AHV
    CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.